Indira Naidu - Immutep Joint Sec
| PRRUF Stock | USD 0.20 0.00 0.00% |
Insider
Indira Naidu is Joint Sec of Immutep Limited
| Phone | 61 2 8315 7003 |
| Web | https://www.immutep.com |
Immutep Management Efficiency
The company has return on total asset (ROA) of (0.2296) % which means that it has lost $0.2296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3849) %, meaning that it generated substantial loss on money invested by shareholders. Immutep's management efficiency ratios could be used to measure how well Immutep manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Mulkerrin | ADC Therapeutics SA | 69 | |
| David Dornan | Elevation Oncology | 47 | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| PharmD Faltaos | Olema Pharmaceuticals | N/A | |
| Marvin Caruthers | Viridian Therapeutics | 85 | |
| MBA MD | Viridian Therapeutics | 72 | |
| Jonathan MBA | Viridian Therapeutics | 49 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
| Peter Kushner | Olema Pharmaceuticals | 85 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| James Spudich | Cytokinetics | 83 | |
| James Balkovec | Cidara Therapeutics | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Stephane Henchoz | ADC Therapeutics SA | N/A | |
| Valerie MD | Elevation Oncology | 47 | |
| Sunil MD | Sana Biotechnology | 54 | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Susan Romanus | ADC Therapeutics SA | 59 | |
| Joanna Siegall | Cytokinetics | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 |
Immutep Limited Leadership Team
Elected by the shareholders, the Immutep's board of directors comprises two types of representatives: Immutep inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immutep. The board's role is to monitor Immutep's management team and ensure that shareholders' interests are well served. Immutep's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immutep's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic MD, Chief Officer | ||
| Deanne LLB, Gen COO | ||
| Indira Naidu, Joint Sec | ||
| Shengfei Fang, F Sec | ||
| Christian Mueller, Director Affairs | ||
| Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee |
Immutep Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immutep a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (7.18) % | |||
| Current Valuation | 142.99 M | |||
| Shares Outstanding | 879.09 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 24.04 % | |||
| Price To Earning | (2.50) X | |||
| Price To Book | 2.81 X | |||
| Price To Sales | 33.12 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Immutep Pink Sheet
Immutep financial ratios help investors to determine whether Immutep Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immutep with respect to the benefits of owning Immutep security.